Results 21 to 30 of about 26,349,951 (265)
Correlation between CA-15-3 and Bone Scan findings in patients with Carcinoma Breast
Asian Pacific Journal of Cancer Biology, 2022 Objectives: Breast cancer is the most common malignant tumor of females; the incidence increases with age. Bone is the most common site to which breast cancer metastasizes.
Julekha Khatun, Tarim Mahmood
doaj +1 more source
Diagnostics, 2023 Tumor marker determinations are valuable tools for the guidance of breast cancer patients during the course of disease. They are assessed on diverse analytical platforms that may be associated with differences according to the methods applied and the ...
Lars Schröder +9 more
doaj +1 more source
Clinical usefulness of cancer markers in primary breast cancer [PDF]
, 2011 The aim of this study was to investigate the diagnostic power of CA 549, MSA and CA 15-3 in identifying breast cancer. The study included 232 patients of which 56 were healthy, 43 had benign breast cancer and 191 with other growths.
Verring, A. +3 more
core +1 more source
Cancer Treatment and Research Communications, 2021 Background: We aimed to evaluate the association of serum carcinoembryonic antigen (CEA) and cancer antigen 15–3 (CA 15–3) levels with clinicopathological parameters in patients with breast cancer (BC) and their efficiency for the prediction of ...
Meliha Melin Uygur, Mahmut Gümüş
doaj +1 more source
Case Reports in Oncology, 2021 A 73-year-old woman with no history of disease was referred to our hospital with fatigue and joint pain. Screening blood test showed that her cancer antigen 15-3 (CA 15-3) serum level was elevated to 36.6 U/mL, and a contrast-enhanced computed tomography
Koichiro Takayama +4 more
doaj +1 more source
Diagnostic and prognostic role of preoperative circulating CA 15-3, CA 125, and beta-2 microglobulin in renal cell carcinoma. [PDF]
Dis Markers, 2014 CA 15-3, CA 125 and β-2 microglobulin are three common tumor markers currently used for diagnosis, prognosis, assessment of therapeutic response, and/or to evaluate recurrence in breast and ovarian cancer and malignant lymphoproliferative disorders ...
Lucarelli G +11 more
europepmc +3 more sources
Clinical validation of the novel CLIA-CA-62 assay efficacy for early-stage breast cancer detection
Frontiers in Oncology, 2023 BackgroundWithout organized screening programs up to 60-70% of breast cancers are diagnosed at advanced stages that have significantly lower five-year survival rate and poorer outcomes, which is a serious global public health problem.
Marina Sekacheva +4 more
doaj +1 more source
Performance Characteristics of Seven Automated CA 15-3 Assays [PDF]
American Journal of Clinical Pathology, 2006 Measurements of serum cancer antigen (CA) 15-3 are used to monitor tumor recurrence and treatment of advanced disease. We evaluated the performance characteristics, including limit of detection, linearity, method comparison, and reference intervals, of 7 automated methods for CA 15-3, including the Access 2 (Beckman Coulter, Brea, CA), ADVIA Centaur ...
Patricia R, Slev +2 more
openaire +2 more sources
Multicenter evaluation of the Abbott IMx CA 15-3 assay [PDF]
Clinical Chemistry, 1996 Abstract We describe a new fully automated procedure for the quantitative measurement of CA 15-3: the microparticle enzyme immunoassay (MEIA) technology developed by Abbott Labs. for the IMx automated immunoassay analyzer. The new IMx CA 15-3 test uses two mouse monoclonal antibodies, 115D8 and DF3.
G J, van Kamp +7 more
openaire +2 more sources
Tumor Markers in Dogs with Mammary Gland Tumors
Acta Veterinaria, 2023 The aim of this study was to determine and compare values of carcinoembryonic antigen (CEA) and cancer antigen (CA 15-3) in 50 bitches with mammary tumors and 150 clinically healthy dogs.
Valencakova Alexandra +4 more
doaj +1 more source